StockNews.com Upgrades Mesoblast (NASDAQ:MESO) to “Hold”

Mesoblast (NASDAQ:MESO) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a report on Friday, January 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $13.67.

Mesoblast Stock Performance

Shares of MESO stock traded down $0.50 on Tuesday, reaching $6.60. 231,085 shares of the company’s stock traded hands, compared to its average volume of 1,747,459. Mesoblast has a 12-month low of $1.61 and a 12-month high of $10.24. The company has a market capitalization of $753.59 million, a P/E ratio of -5.89 and a beta of 3.59. The business’s 50 day moving average price is $3.99 and its two-hundred day moving average price is $2.81.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Mesoblast stock. Prosperity Wealth Management Inc. bought a new stake in Mesoblast Limited (NASDAQ:MESO) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 64,150 shares of the company’s stock, valued at approximately $79,000. 1.43% of the stock is owned by institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.